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Recently, a large body of evidence has shown that the microenvironment of in-
vasive breast carcinoma affects its development and the patient’s outcome, and 
vice versa – cancer cells express factors that modulate tumour milieu in terms 
of its composition and function. We performed an immunohistochemical (IHC) 
staining of 108 formalin-fixed, paraffin-embedded (FFPE) tissue samples to in-
vestigate the relationships between T-cell, B-cell, and NK-cell infiltrate, invasive 
breast carcinomas molecular subtypes, and other prognostic indicators. The main 
findings of our study were as follows: the significantly higher infiltrate of the anal-
ysed immune cell subsets in triple-negative (TNBC), HER2-positive, non-luminal 
and luminal B/HER2+ breast carcinomas than in luminal A cancers; their higher 
densities in poorly differentiated lesions; correlations between lymphoid cells and 
the expression of hormonal receptors, HER2 receptor status, and marker of can-
cer proliferation. Furthermore, we observed T-cell numbers to be associated with 
greater tumour diameter. In summary, the results of our study indicate associations 
between tumoural lymphoid infiltration and the unfavourable intrinsic subtypes as 
well as other detrimental prognostic factors in invasive breast carcinomas.
Key words: breast cancer, T-lymphocytes, B-lymphocytes, natural killer cells, 
tumour microenvironment.
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Introduction
Regarding its biology and morphology, breast car-
cinoma is considered as a heterogenous disease. On 
the basis of distinct genetic patterns, several molecu-
lar subtypes, differing in their clinical behaviour, are 
distinguished in invasive breast tumours [1, 2]. In 
routine pathology these subtypes are roughly deter-
mined by immunohistochemistry; the stratification 
of invasive breast tumours into luminal A, luminal B 
(with or without HER2 overexpression), non-luminal 
HER2-overexpressing, and triple-negative pheno-
type significantly influences the patient’s treatment 
and prognosis [1, 3]. Recently, immune cell infiltrate 
has emerged as a new prognostic biomarker in this 
malignancy [1, 2]. 
Inflammatory infiltrate in tumour microenviron-
ment comprises many cell populations that exert 
a diverse effect on cancer cells, ranging from promot-
ing tumour development to suppressing its growth. 
The cancer-immune cell interplay results from the di-
rect cell-to-cell contact or is mediated by lymphoid 
cell-derived molecules, e.g. receptors, cytokines, 
and chemokines. There is growing evidence that 
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interactions between neoplastic and immune cells 
affect the patient’s outcome [4, 5, 6, 7, 8, 9]. The can-
cer milieu includes lymphoid cells, with tumour-in-
filtrating T- and B-lymphocytes as well as natural 
killer (NK) cells. These represent both the adaptive 
and the innate branch of immune response. Concern-
ing T-cells, several subgroups, which differ in their 
function, phenotype, and cytokine profile, are dis-
tinguished. The activity of respective T-cell subsets 
ranges from cytotoxicity towards malignant cells and 
anti-tumour response enhancement to immunotoler-
ance induction and immune suppression [4, 6, 10]. 
Moreover, tumour-infiltrating B-lymphocytes were 
reported by some authors to be a source of anti- 
tumour antibodies [11]. Similarly to some T-cells, 
the propensity of cancer-related NK cells to control 
tumour growth and its spread is mainly attributed to 
their cytotoxic activity [12, 13]. Hence, both cellular 
and humoural immune response are involved in com-
plex tumour-host interactions [14, 15]. 
Recently, more and more evidence is emerging 
that tumour-infiltrating cells are substantially af-
fected by both the cancer cells and other elements 
of the environment. These alterations may involve 
their composition and function as well as recruitment 
to the tumour site. This is due to the molecules se-
creted and expressed by both malignant and stromal 
cells as well as metabolic alteration within malignant 
tissue. Nutrient depletion and the accumulation 
of waste products in the tumour may promote immu-
nity suppression [16, 17, 18, 19]. On the other hand, 
apoptosis-associated change in the expression of sur-
face and cytoplasmatic tumoural antigens was sug-
gested to enhance immune reaction, a phenomenon 
observed in highly proliferative tumours and during 
chemotherapy [10, 14, 20, 21]. Several authors 
postulated the prognostic value of tumour-infiltrat-
ing lymphocyte density and their subpopulations in 
breast cancer [7, 21, 22], and some even indicated 
that immune-derived parameters may have stronger 
prognostic value than tumour-based markers [23]. 
Thus, the evaluation of tumour-infiltrating lympho-
cytes (TILs) in breast cancer has recently been pro-
posed as a novel, supplemental indicator of patient 
outcome due to its possible clinical relevance [7]. 
In future, more research into immune cell involve-
ment in breast cancer progression may contribute to 
the development of immunotherapy – a new ther-
apeutic approach aimed at evoking strong effective 
anti-tumour response as well as at breaking cancer 
cell escape from immunosurveillance [6, 9, 13, 20, 
24, 25, 26].
The aim of our study was to evaluate the densities 
of tumour-infiltrating T-cells, B-cells, and NK cells 
in breast cancers of different molecular subtypes, and 
to investigate their associations with other prognostic 
markers in this malignancy.
Material and methods
Materials
The materials comprised routinely processed, for-
malin-fixed, paraffin-embedded tissues of primary in-
vasive breast carcinomas diagnosed between 2002 and 
2014. Patients who had received presurgical chemo-
therapy were excluded from the study. The archival 
haematoxylin-eosin-stained slides were re-evaluated, 
and representative, well-preserved specimens were 
chosen for immunohistochemistry. The Nottingham 
Histologic Grade system was used for the grading, 
while the staging was performed according to the 8th 
edition of the AJCC system [27].
Immunohistochemistry
The specimen processing was largely performed in 
accordance with the previously described methodolo-
gy [28]. Immunohistochemistry (IHC) for CD45RO, 
CD20, CD56, estrogen receptor (ER), progesterone 
receptor (PR), and Ki67 protein was performed ac-
cording to the protocol routinely used in our labora-
tory. The selected blocks were cut into 4-μm-thick 
sections. Antigen retrieval was performed by incu-
bating the slides in citrate buffer (pH 6.0; 0.01M) or 
EDTA (pH 8.0; 0.01M) at 97°C in a water bath for 
40 and 30 minutes, respectively. UltraVision Quan-
to detection system (Lab Vision, ThermoScientific, 
USA) and 3,3’-diaminobenzidine as chromogen were 
used, and the slides were counterstained with Mayer 
haematoxylin (Thermo Fisher Scientific, Waltham, 
USA) and coverslipped. Immunohistochemistry for 
HER2 (PATHWAY 4B5, Ventana Medical System 
Inc., USA) was performed automatically on Bench-
Mark BMK Classic autostainer (Ventana, USA) using 
UltraVIEW DAB Detection Kit (Ventana Medical 
Systems Inc., USA). The primary antibodies used in 
the study are listed in Table I. 
For specimens with HER2 status 2+ in immuno-
histochemistry results, fluorescence in situ hybridisa-
tion (FISH) was conducted. FISH was performed us-
ing a PathVysion HER-2 DNA Probe Kit II (Abbott 
Molecular, USA) according to the manufacturer’s pro-
tocol. In short, paraffin blocks were cut into 4-μm-
thick sections. Hybridisation was performed at 37°C 
for 14 to 18 hours with a Locus Specific Identifier (LSI) 
DNA probe (app. 226 kb) SpectrumOrange directly 
labelled (Abbott Molecular, USA) and a Chromosome 
Enumeration Probe 17 (CEP17) satellite DNA probe 
(app. 5.4 kb) SpectrumGreen directly labelled (Abbott 
Molecular, USA). 4,6-diamino-2-phenylidole (DAPI) 
was used as a nuclear counterstain. The LSI HER-2/
neu and CEP17 signals were counted on a fluores-
cence microscope equipped with specific filter sets, and 
HER-2/neu to CEP17 ratio > 2.0 was considered as 
HER2/neu overexpression [29].
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Evaluation of immunostaining
The slides stained for CD45RO, CD20, and CD56 
were initially scanned on a Nikon Labophot-2 optical 
microscope (Tokyo, Japan) at a very low magnifica-
tion (25×) to select areas of the highest positive cell 
infiltrate. For research purposes, three scoring sys-
tems were applied to the study: 
1. The densities of investigated CD45RO– and 
CD20-positive cells (T- and B-cells, respectively) 
were evaluated under a low magnification (100×), 
as a percentage of tumour tissue area occupied by 
positively stained cells. The cells located no farther 
than one 100× power field from the tumour edge 
were regarded as “invasive margin”. Intratumoural 
population was determined as positively-stained 
cells located within cancer cell islets or surrounding 
cancer islets, with direct contact to neoplastic tissue. 
The cell density was evaluated as an average val-
ue scored in 5 power fields of the highest lymphoid 
infiltrate.
2. The intensity of CD45RO and CD20-positive 
cell infiltrate was additionally evaluated in accor-
dance with the system of Kreike et al. [30]. The grad-
ing was as follows: 0 – none, 1 – weak, 2 – moderate, 
and 3 – intensive lymphoid infiltrate.
3. For evaluation of CD56-positive (NK) cells, 
the positively-stained cells were first scanned at a low 
magnification (100×) and the areas with the highest 
number of positive cells were chosen. Then, positive-
ly stained cells were counted in five high-power fields 
(HPF; 400×, 0.2 mm2 field area), which represented 
1 mm2 of the examined tissue. The cells located no 
farther than one HPF from the tumour edge were re-
garded as “invasive margin”. The intratumoural pop-
ulation was determined as positively-stained cells lo-
cated within cancer cell islets or the positively-stained 
cells surrounding cancer islets, with direct contact to 
neoplastic tissue.
Positive ER and PR expression were set when ≥ 1% 
of neoplastic cells showed positive immunostaining. 
The threshold for discriminating between low and 
high Ki67 expression was set at ≥ 20% of positive 
cells. Scoring of the HER2 staining was performed by 
standard method [29].
Definition of breast cancer molecular subtypes 
The cases were classified into molecular subtypes 
according to St Gallen 2015 International Expert 
Consensus [31]: luminal A (ER+ and PR ≥ 20%, 
Ki67 < 20%, HER2–), luminal B/ HER2– (ER+, 
HER2– with PR < 20% and/or Ki67 ≥ 20%), lumi-
nal B/ HER2+ (ER+ or PR+, HER2+), HER2+ 
non-luminal (ER–/PR–/HER2+), and triple-nega-
tive breast cancer (ER–/PR–/HER2–). 
Results
Description of the study group
The study group consisted of 108 primary invasive 
breast cancer female patients. The average patient 
age at the time of diagnosis was 55 years (range: 29- 
87 years). Regarding the stage of the disease, 42 (38.9%) 
cases were classified as stage I, 41 (38.0%) as stage II, 
24 (22.2%) as stage III, and 1 case (0.9%) as stage IV. 
Tumour sizes were as follows: pT1 – 60 (55.5%), 
pT2 – 45 (41.7%), and pT3 – 3 cases (2.8%). Con-
cerning lymph node status, 54 (50.0%) patients had 
no nodal involvement (pN0), while 31 (28.7%) were 
of stage pN1, 9 (8.3%) of stage pN2, and 13 (12.0%) 
of stage pN3. Nottingham Histologic Grade distri-
bution was as follows: G1 – 17 (15.7%), G2 – 37 
(34.3%), and G3 – 54 (50.0%) cases. With respect 
to the histologic type, 91 cases (84.3%) were clas-
sified as invasive carcinoma not otherwise specified 
(NOS), 15 (13.9%) cases were of lobular histology 
(CLI), while for 2 cases (1.8%) the histologic type was 
determined as “other”. 
Distribution of molecular subtypes was as follows: 
luminal A – 36 (33.3%), luminal B – 14 (13.0%), lu-
minal B/HER2+ – 10 (9.3%), non-luminal HER2+ 
– 20 (18.5%), and triple-negative breast cancer 
(TNBC) – 28 (25.9%) cases. 
Differences in lymphocytic infiltrate between 
respective breast cancer molecular subtypes 
First, the differences in tumour area occupied by 
T-cell, B-cell, and NK cell infiltrate were investigat-
ed between tumours of either luminal or non-luminal 
Table I. Antibodies used in the study
clOne dilutiOn antigen retrieval incubatiOn time manufacturer
CD45RO UCHL1 1 : 100 Citrate 30 min Dako, USA
CD20 L26 1 : 50 Citrate 30 min Dako, USA
CD56 MLQ-42 1 : 100 Citrate 30 min Cell Marque, USA
Estrogen receptor 6F11 1 : 25 Citrate 60 min Novocastra (Leica 
Biosystems, Germany)
Progesterone receptor PgR636 1 : 50 Citrate 60 min Dako, USA
Ki67 MIB-1 1 : 100 EDTA 60 min Dako, USA
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phenotype. The significantly higher densities of T- and 
B-lymphocytes, both in intratumoural area and at 
the invasive margin, were observed in non-luminal 
tumours, as compared with luminal ones. A similar 
observation was made for NK cells at the tumour 
edge (Table II). Then, the evaluation with reference to 
breast cancer molecular subtypes was performed (in 
accordance with St Gallen 2015 recommendations). 
The density of intratumoural T-cells was signifi-
cantly higher in TNBC than in luminal A tumours 
(p < 0.015). Likewise, luminal A subtype was asso-
ciated with lower T-lymphocyte densities at the in-
vasion front in comparison with TNBC (p < 0.001), 
HER2+ non-luminal (p < 0.001), and luminal B/
HER2+ (p < 0.005) tumours. Statistically signif-
icant differences in intratumoural B-cell infiltrate 
between respective subtypes were observed in Krus-
kal-Wallis ANOVA test exclusively. For this subpop-
ulation, the cell density increased from luminal A and 
B tumours to HER2+ non-luminal and TNBC can-
cers. B-cell infiltrate at the invasive edge was more 
abundant in TNBC and HER2+ non-luminal tu-
mours as compared to luminal A lesions (p < 0.03 
and p < 0.002, respectively). With reference to NK 
cells, the only statistically significant differences were 
observed at the tumour invasive margin. The cell 
densities were significantly lower in luminal A and 
B in comparison with TNBC cancers (p < 0.001 and 
p < 0.3, respectively; Table II, Fig. 1A).
As far as the luminal subtypes were concerned, in-
creased T-cell infiltrate of luminal B/HER2+ invasive 
margin, in comparison with luminal A cancers, were 
the only statistically significant differences observed, 
according to St Gallen either 2015 or 2013 classi-
fication (Ki67 expression cut-off ≥ 20% or ≥ 14%, 
respectively; p < 0.003). However, the infiltrates 
of all investigated subsets were highest in luminal 
B/HER2+ tumours. None of the analysed immune 
cell subpopulations differed significantly in their 
quantities between luminal A and B cancers, regard-
less of the St Gallen classification applied. 
The evaluation of T- and B-cell infiltrate intensive-
ness, performed according to the system of Kreike 
et al., was partially concordant with the above-men-
tioned results. Statistically significant differences 
between groups were observed for T-lymphocytes 
at the invasive margin (p < 0.006), as well as for 
B-cells, both within the tumour bed and at the in-
vasive front (p < 0.035 and p < 0.03, respectively). 
Once again, the immune cells were less abundant 
in luminal A and B cancers compared to HER2+ 
non-luminal and TNBC lesions. The differences, 
however, did not reach statistical significance in post-
hoc test (Fig. 1B).
All analysed immune cell populations, excluding 
intratumoural NK cells, showed slight to moderate 
negative correlations with both the ER and the PR 
expression, as well as positive correlations with 
the expression of Ki67 and mitotic index. However, 
the only immune cell populations that displayed cor-
relation with HER2 expression were T- and B-cells 
located at the invasive margin (data not shown). 
Almost all of the investigated immune cell sub-
sets were increased in highly proliferating tumours 
(Ki67 ≥ 20%), with the exception of intratumoural 
NK cells (Table II). Similar results were obtained with 
the system of Kreike et al. for T-cells and B-cells at 
the invasion front exclusively. The increased numbers 
of T- and B-lymphocytes at the invasion edge were 
also observed in HER2-overexpressing tumours, both 
when evaluated as a percentage of the tumour area 
involved or according to the system of Kreike et al. 
(Table II). 
Associations between lymphocytic infiltrate  
and other prognostic indicators in breast cancer
For all the analysed immune cell populations, 
the percentage of the tumour area infiltrated by 
immune cells differed significantly between lesions 
of respective Nottingham Histologic Grade. The in-
filtrates of either T- or B-cells, both within tumour 
nest and at the invasive margin, as well as of NK 
cells at the invasion front, were significantly low-
er in G1 and G2 than in G3 cancers (the highest p 
value < 0.01). Regarding intratumoural NK cells, 
the differences were only found between G2 and G3 
cancers (Table III, Fig. 2A). Similar results were ob-
tained with the scoring system of Kreike et al. for 
T-cells (both in intratumoural area and at the tumour 
edge) as well as for intratumoural B-cells (p < 0.001). 
With reference to B-lymphocytes of the invasive 
margin, the statistical significance between groups 
was reached in Kruskal-Wallis ANOVA exclusively 
(p < 0.04, Fig. 2B). 
Regarding pTNM staging, we found T- and 
B-cell infiltrates of the invasion front to be signifi-
cantly less abundant in stage I cases in comparison 
with stage II patients (p < 0.04, Table III). No 
statistically significant associations with the stage 
of the disease were obtained with the system 
of Kreike et al.
A higher percentage of the tumour area infiltrated 
by T-cells was observed in cancers of diameter larger 
than 2 cm (pT > 1) in comparison with pT1 tumours 
(tumour bed population – p < 0.02, invasion margin 
– p < 0.03, Table III). When the system of Kreike 
et al. was applied, only the higher intratumoural 
T-cell infiltrate density was significantly associated 
with greater tumour size. Regardless of the evalua-
tion system applied, no differences in lymphocytic 
densities were found between tumours with various 
lymph node status (data not shown). 
Regarding the histologic type, a higher num-
ber of T- and B-cells at the invasive margin was 
174
AnnA GlAjcAr, joAnnA Szpor, KAtArzynA EwA tyrAK, et al.
A
B
Fig. 1. The densities of T-cells, B-cells, and NK cells with reference to St Gallen 2015 molecular subtype. A) Immune 
cell quantities evaluated as a percentage of tumour area involved; B) Infiltration density assessed by the scoring system 
of Kreike et al. Central point is the arithmetic mean, box is the arithmetic mean ± standard error, and whisker is the 
arithmetic mean ± standard deviation. ANOVA Kruskal-Wallis test
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Fig. 2. The densities of T-cells, B-cells, and NK cells with reference to Nottingham Histologic Grade. A) Immune cell 
quantities evaluated as a percentage of tumour area involved; B) Infiltration density assessed by the scoring system of 
Kreike et al. Central point is the arithmetic mean, box is the arithmetic mean ± standard error, and whisker is the arith-
metic mean ± standard deviation. ANOVA Kruskal-Wallis test
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Fig. 3. Lymphoid infiltration of invasive breast cancer tissue. Abundant and low densities of T-cells (A, B), B-cells 
(C, D), and NK cells (E, F). Immunohistochemical staining for CD45RO, CD20, and CD56, light microscopy, magnifi-
cation used: 50× (A-D) and 100× (E, F).
A B
C D
E F
observed in NOS cancers, as compared to CLI lesions 
(Table III). This observation was significant either 
when the percentage of the infiltrated tumour area 
or the system of Kreike et al. was concerned (data not 
shown). 
Discussion
Although determining the molecular subtypes 
has become standard in breast cancer management, 
the information concerning the relationship between 
the molecular and immune phenotype of the tumour 
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is scarce and, to a certain extent, inconclusive. More 
abundant lymphocyte infiltrate observed by some 
authors in non-luminal breast cancer tumours, as 
compared to the luminal ones, was suggested to be 
associated with their more aggressive profile, genetic 
instability, HLA-G expression, and distinct metab-
olism [21, 24, 32, 33]. Moreover, intense immune 
infiltration as well as higher cytokine level were re-
ported in high-grade, hormone receptor-negative 
[8, 23, 34, 35], and HER-2 overexpressing breast 
tumours [8, 34, 35]. To date, it was shown that 
the clinicopathological significance of TILs in breast 
cancer is phenotype-dependent and ranges from their 
anti-tumour to pro-tumourogenic properties because 
the more prominent lymphocytic infiltrate was asso-
ciated with either more beneficial prognosis in TNBC 
[24] and ER–/HER2+ [21, 34] lesions or with 
an unfavourable patient outcome in ER+ cancers 
[34]. Similarly, Nagalla et al. observed that the im-
mune gene expression was either a beneficial indica-
tor of distant metastasis-free survival in highly and 
intermediately proliferative or an adverse factor in 
low proliferative cancers [36]. This was also support-
ed by other studies, which pointed out that the im-
pact of immune metagene on the prognosis depended 
on both the molecular subtype and the proliferation 
status of breast tumour [36, 37]. 
Out of all the TILs, T-cells are considered as 
a prevailing subpopulation [4, 6, 8, 38, 39]. In our 
study more abundant T-cell infiltrate was associated 
with more aggressive breast cancer molecular sub-
types: TNBC, HER2+ non-luminal, and luminal 
B/HER2+. Moreover, differences between luminal A 
and TNBC lesions concerned both the tumour nest 
and its immediate surrounding. A similar observation 
was made by Cimino-Matthews et al., who described 
a higher T-cell infiltration in human primary TNBC 
as compared with luminal tumours [38]. Some au-
thors postulated associations between tumour infil-
trating T-cell quantity and ER- as well as PR-nega-
tivity [40], which is in accordance with our results, 
while others did not [41]. Research into microinva-
sive breast cancer provided a hypothesis on immu-
nogenicity of HER2-overexpressing tumours, which 
leads to the accumulation of cytotoxic T-cells, and, 
finally, to the rupture of the basement membrane 
[42]. Moreover, among luminal lesions, we noted 
that T-cells located at the invasive front of malignant 
lesions were the only subpopulation that differed 
significantly, with their highest density in luminal 
B/HER2+ lesions. Thus, we hypothesise that HER2 
overexpression influences T-lymphocyte response (or 
vice versa) to a greater extent than is achieved by 
the higher proliferation and the decrease in hormone 
receptors (two factors that discriminate between lu-
minal A and B cancers). Our observation of T-cells 
being more numerous in high-grade breast tumours 
than in more differentiated lesions is corroborated by 
results from other study groups [39, 43]. Two expla-
nations for this phenomenon are offered: the T-cell 
contribution to the cancer aggressiveness or the im-
pact of high-grade tumours on immune response [38, 
41]. We found that T-lymphocytes were the only pop-
ulation significantly increased in tumours of greater 
diameter. On the other hand, some authors indicated 
smaller tumour diameter, lower grade, fewer positive 
lymph nodes, and longer survival as characteristic 
of invasive breast ductal carcinomas abounding in 
T-cells [44]. These were suggested to control tumour 
progression due to their ability to eliminate cancer 
cells and to prevent metastasis formation [44, 45]. 
Such a hypothesis was supported by a study in a mu-
rine model, in which tumour-specific T-cells were 
noticed in bone marrow. After stimulation the cells 
penetrated the malignant breast tumour and reduced 
its size [46]. Interestingly, along with an increase in 
the histologic grade of an early breast cancer, a shift 
from a naive towards a memory and an activated 
T-cell phenotype was observed [47].
The crosstalk between T-cells and breast cancer 
is complex. Fu et al. proposed a hypothesis of T-cells 
influencing fibroblast function, which in turn may 
promote tumour progression. In addition, the au-
thors observed a high ratio of regulatory T-lympho-
cyte subpopulation within breast cancer tissue [16]. 
On the other hand, an increased percentage of cyto-
toxic T-cells in primary breast tumour site may indi-
cate a favourable prognosis [23]. Our study showed 
that more abundant T-cell densities were associated 
with adverse pathological prognostic factors, such 
as greater tumour size, HER2-overexpression, and 
higher proliferation rate. Interestingly, the increased 
T-cell density in breast tumour stroma and within 
tumour nest was reported to correlate with longer 
survival [41]. Moreover, a higher prevalence of T-cell 
than B-cell fraction was proposed as the indicator 
of pathological complete response (pCR) after che-
motherapy [8].
To date, an exploration of B-cell densities with ref-
erence to breast cancer intrinsic subtype was under-
taken only by a few research groups. In a study by 
Mahmoud et al. on invasive ductal carcinomas, high 
B-cell infiltrate correlated with the lack of ER and PR 
expression and basal-like phenotype, either in distant 
or adjacent stroma as well as intratumourally [15]. 
This, in general, is in accordance with our study, 
although we found that the correlations between 
B-cells and hormone receptor status are not strong. 
On the other hand, more numerous total B-cells in 
tumour tissue resulted in a favourable outcome, par-
ticularly in high-grade, ER-negative, HER2-overex-
pressing, and basal-like carcinomas [15]. The diverse 
infiltrate is presumed to persist and even deepen as 
cancer spreads, with decreased B-cell densities in 
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TNBC secondary tumours as compared to luminal 
metastases and primary lesions [38]. More numer-
ous B-lymphocytes were associated with positive 
HER2 status in primary invasive [40] and high-grade 
ductal cancers [15, 23]. In line with these findings, 
we observed B-cells to be increased in non-luminal 
(HER2-overexpressing and TNBC), HER2-overex-
pressed, highly proliferating, and poorly differenti-
ated breast tumours. With the exception of the last 
two groups, the differences were more pronounced 
at the tumour edge; however, regarding the intrin-
sic subtype, luminal A and B cancers were less infil-
trated also intratumourally. Interestingly, one study 
observed significantly higher B-cell quantities in G3 
within the breast tumour area exclusively [48], and 
some authors did not observe any associations with 
cancer differentiation [39]. Similar to the T subset, 
the average number of B-lymphocytes was higher 
in luminal B/HER2+ than in the remaining lumi-
nal tumours; however, the relationship did not reach 
statistical significance. Although luminal A and B 
cancers appear to be closely related, these tumours 
are distinct entities, with a diverse genetic alteration 
pattern [49], which do not seem sufficient to trans-
late to varied immune response.
In HER2-negative invasive ductal breast lesions, 
B-cell proliferation and affinity maturation were 
suggested to occur at the tumour site and to be an-
tigen-driven [20, 50, 51]. This supported the hy-
pothesis of spontaneous specific humoural response 
to neoplastic cells [20, 50]. In medullary breast car-
cinoma, cancer-associated B-cells are a source of an-
tibodies binding to β-actin, which is expressed on 
the surface of cancer cells during apoptosis [11]. It 
is thought that the interplay between T- and B-cells 
results in their mutual stimulation and, consequent-
ly, in enhanced immunosurveillance [52]. Conversely, 
the development of the regulatory subset of B-lym-
phocytes, in the presence of mammary adenocarci-
noma cells, was observed in a murine model; these, 
in turn, mediate T-cell conversion into a regulatory 
subset [53]. Some authors postulate that tumoural 
lymphocytes display the ability to express metallo-
proteinases, which mediates the recruitment of oth-
er immune cells, and consequently promotes cancer 
progression [17]. Thus, the impact of the microen-
vironmental B-cells on breast cancer may be two-
fold, with their pro-tumourogenic activity on the one 
hand and the enhancement of anti-tumour proper-
ties on the other. Moreover, the existence of multi-
ple B-lymphocyte subsets that differ with respect to 
their phenotype and function is postulated by some 
authors [25].
The published literature on the relationships be-
tween the quantities of NK cells and the molecu-
lar subtype of breast cancer is scarce, and so far no 
significant differences have been shown. However, 
Engels et al. postulated an increased amount of NK 
cells as one of the positive prognostic factors in lumi-
nal A cancers [54]. Moreover, pathological response 
of HER2-overexpressing tumours to trastuzumab 
therapy is partially dependent on the enhanced ac-
tivation of NK cells in reaction to the antibody [13, 
21, 22]. We found NK cell infiltrate to be less abun-
dant in luminal as compared with TNBC tumours, 
but the significance was noted only with reference to 
the invasive margin population of these cells. Because 
no significant differences were observed in the NK cell 
densities between luminal tumours, with their slight 
increase in luminal HER2-enhanced cancers, more nu-
merous NK cells at the invasive edge of high-prolifer-
ating tumours may be explained by higher densities 
of this population in non-luminal lesions. The higher 
intratum oral tumoural NK cell infiltration observed 
in NOS breast cancers was related to higher grade, 
greater tumour size, and nodal involvement [48]. 
In contrast, in our study high histologic grade was 
associated with more numerous NK cells at the inva-
sive margin and no relationship with tumour diameter 
was obtained. Furthermore, some authors noted a lack 
of NK cells within neoplastic lesions of the breast [55], 
which is discordant with our study.
NK cells were proposed as part of an important 
barrier against metastasising in invasive breast tu-
mours [56]. The expression of NK cell activation and 
signalling-associated markers, as well as NK cell in-
teractions with dendritic cells and macrophages, were 
related to longer overall and recurrence-free survival 
in breast cancer patients in the study by Ascierto et 
al. [12]. In contrast, the activity of genes for CD56, 
which was considered by some authors as a marker 
of immature NK cell subgroup [57], did not exhib-
it any relationship with cancer progression [12]. It 
is worth noting that the NK cell function is highly 
dependent on tumour-derived molecules [12, 13], 
and the existence of several distinct NK cell sub-
sets was postulated by some authors [58]. In certain 
studies, their cytotoxicity was suggested to increase 
in the presence of mammary cancer cells [58], while 
other studies pointed out that breast cancer cells 
may considerably inhibit the NK cell cytolytic func-
tion, and thus promote immune escape [57]. Sever-
al explanations were proposed for this phenomenon: 
an alteration in the expression of receptors and their 
ligands on NK cells with their shift towards the in-
hibitory phenotype; an increased expression of can-
cer-derived molecules, which negatively influences 
NK cell activity; and a blockade in their terminal 
maturation at the tumour site [57].
In summary, our results point out the relation-
ships between lymphoid infiltrate and adverse clin-
icopathological factors in invasive breast cancer, par-
ticularly with its less favourable molecular subtypes. 
Moreover, the differences obtained in our study varied 
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with reference to immune cell subsets and their lo-
cation within tumour tissue. The latter observation 
was most apparent for the NK cells, whose number 
differed significantly only at the invasive margin, 
when breast cancer intrinsic subtype or proliferation 
status were concerned. This might be due to the poor 
immune cell penetration or the intratumoural popu-
lation being influenced more by cancer-derived mole-
cules. Considering their “native” properties, either T, 
B, or NK cell functions appear to be altered within 
the cancer microenvironment, both intratumourally 
and in tumour stroma. It is suggested that changes 
in quantities of the respective immune cell popula-
tions may reflect an increase in total TILs [7]. Our 
previous study on mast cells, however, challenges 
these results because higher mast cell numbers were 
observed in luminal breast cancers [28], which are 
usually regarded as less infiltrated tumours [8, 21, 
24]. Thus, further research concerning the tumour 
microenvironment is needed to elucidate its complex 
relationships with breast cancer molecular subtypes.
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